The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter.
- Biotechnology OTC Pharmaceutical Prescription Drugs Valuation
Computer Fraud and Abuse Act
Back to Top